Exact Sciences Stock
€51.25
Your prediction
Exact Sciences Stock
Pros and Cons of Exact Sciences in the next few years
Pros
Cons
Performance of Exact Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exact Sciences | -1.640% | 5.160% | 36.478% | 9.267% | -6.878% | 1.902% | -33.890% |
| Regeneron Pharmaceuticals Inc. | 1.810% | 2.234% | 7.211% | -41.257% | -21.526% | -14.470% | 3.936% |
| Incyte Corp. | 2.110% | 3.501% | 10.903% | 8.114% | -13.634% | -19.122% | -34.669% |
| Amgen Inc. | -0.510% | -0.888% | 0.677% | -14.626% | -2.036% | 6.186% | 17.976% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Taking an initial glance at the financial statements of EXACT Sciences Corporation (EXAS), a company notable in the Biotechnology & Medical Research industry, reveals the company's remarkable strategic focus in the sector. Although immediate profitability appears challenged given the absence of a positive net income, it is clear the company has been diligently investing in robust Research and Development efforts and increasing its selling, general, and administrative expenses possibly to build brand recognition and market share.
Looking into the finer details warrants a more nuanced understanding of both the potential opportunities as well as risks associated with EXACT Sciences Corporation (EXAS).
1. Strong Revenue Growth: One of the most positive aspects in the financials of EXAS is its impressive year-on-year revenue growth. The company's total revenue increased from nearly $1.5B in 2020 to over $2B by the end of 2022. This consistent increase in revenue indicates a well-received portfolio of products in a market with probable high growth demand.
Comments
